Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.42 |
| ▸ | MTOR | P42345 | 4/20 | 0.42 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | TYK2 | P29597 | 3/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12108382 | 0.91 | METTL3 (0.41) | PIK3CAMTORMETTL3PRKAG1PRKAA1 | |
| SCHEMBL12108361 | 0.88 | METTL3 (0.46) | PIK3CAMETTL3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL12108378 | 0.87 | METTL3 (0.43) | METTL3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL12108363 | 0.84 | METTL3 (0.48) | METTL3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL13771684 | 0.84 | METTL3 (0.48) | METTL3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL12108368 | 0.84 | METTL3 (0.48) | METTL3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL12108370 | 0.82 | METTL3 (0.44) | METTL3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL12108387 | 0.82 | METTL3 (0.46) | METTL3 | |
| SCHEMBL12108373 | 0.81 | METTL3 (0.42) | METTL3 | |
| SCHEMBL12108401 | 0.81 | METTL3 (0.42) | METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | PIK3CA 66/4885MTOR 3132/4885METTL3 2709/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | PIK3CA 66/4885MTOR 3132/4885METTL3 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.